Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
Noise & Health  
 Next article
 Previous article
Table of Contents

Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Citation Manager
Access Statistics
Reader Comments
Email Alert *
Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded28    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


Year : 2014  |  Volume : 16  |  Issue : 72  |  Page : 257--264

Renexin as a rescue regimen for noise-induced hearing loss

Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea

Correspondence Address:
Dr. Shi Nae Park
Department of Otorhinolaryngology -Head and Neck Surgery, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701
Login to access the Email id

Source of Support: The National Research Foundation of Korea (2010-0004744 and 2013-011870) and SK Chemicals., Conflict of Interest: None

DOI: 10.4103/1463-1741.140497

Rights and Permissions

Renexin, a compound of cilostazol and ginkgo biloba extract, has been reported to produce neuroprotective effects through antioxidant, antiplatelet, and vasodilatory mechanisms. This study was designed to investigate the protective effects of renexin on hearing, the organ of Corti (OC), and medial olivocochlear efferents against noise-induced damage. C57BL/6 mice were exposed to 110 dB SPL white noise for 60 min and then randomly divided into three groups: high- and low-dose renexin-treated groups and noise only group. Renexin were administered for 7 days: 90 mg/kg to the low-dose, and 180 mg/kg to the high-dose groups. All mice, including the controls underwent hearing tests on postnoise day 8 and were killed for cochlear harvest. We compared the hearing thresholds and morphology of the OC and cochlear efferents across the groups. The renexin-treated groups recovered from the immediate threshold shifts in a dose-dependent manner, while the noise group showed a permanent hearing loss. The renexin-treated ears demonstrated less degeneration of the OC. The diameters of the efferent terminals labeled with α-synuclein were preserved in the high-dose renexin-treated group. In the western blot assay of the cochlear homogenates, the treated groups displayed stronger expressions of α-synuclein than the noise and control groups, which may indicate that noise-induced enhanced activity of the cochlear efferent system was protected by renexin. Our results suggest that pharmacologic treatment with renexin is hopeful to reduce or prevent noise-induced hearing loss as a rescue regimen after noise exposure.


Print this article     Email this article